The independent source for health policy research, polling, and news.
1,101 - 1,120 of 3,876 Results
The U.S. Labor Department investigates Noble Health after former employees of its shuttered Missouri hospitals say the private equity-backed owner took money from their paychecks and then failed to fund their insurance coverage.
Nonprofit RIP Medical Debt buys up unpaid hospital bills plaguing low-income patients and frees them from having to pay.
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn’t materialized.
Under the Medicare drug negotiations provisions in the reconciliation bill, the federal government would see its outlays reduced by about $300 billion. That reduction wouldn’t result from cuts in benefits. Instead, Medicare would be empowered to leverage its market power to pay lower prices for certain drugs.
A TV and social media ad offers a reason to check on the enforcement of a sweeping rule that requires hospitals to post information about what they charge insurers and cash-paying patients.
Since the U.S. Supreme Court overturned Roe v. Wade in June, ER doctors say they — and their patients — are trapped between state anti-abortion laws and the federal law requiring that care be delivered in emergency situations. Women’s lives hang in the balance.
Republicans say Democrats are wrong to claim that birth control could be the Supreme Court’s next target. But Democrats have plenty of evidence that it might be.
In the first official test vote since the Supreme Court overturned Roe v. Wade, voters in Kansas’ primary said in no uncertain terms they want to keep a right to abortion in their state constitution. Meanwhile, the Senate is still working to reach a vote before summer recess on its health care-climate-tax measure, but progress is slow. Tami Luhby of CNN, Sandhya Raman of CQ Roll Call, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Bram Sable-Smith, who wrote the latest KHN-NPR “Bill of the Month” installment about a very expensive ambulance trip.
Her doctor told her the noninvasive genetic test would be $99. When she called, she was told $250 and if she didn't pay quickly it could be $800.
More than two years into the pandemic, parents face a child care crisis. That’s why some hospitals are considering starting child care centers to address recruitment and retention troubles.
Private equity firms are seeing opportunities for profit in hospice care, once the domain of nonprofit organizations. The investment companies are transforming the industry — and might be jeopardizing patient care — in the process.
Debt lawsuits — long a byproduct of America’s medical debt crisis — can ensnare not only patients but also those who help sick and older people be admitted to nursing homes, a KHN-NPR investigation finds.
Health insurers and self-insured employer plans are now required to post their negotiated rates for almost every type of medical service. But navigating through the trove of information is no easy task.
State and federal laws require health plans to offer accurate lists of participating doctors and facilities, but consumers still struggle to get timely appointments with providers.
Families affected by ultra-rare diseases are starting their own companies to speed the development of treatments for their kids, venturing into territory that traditional drugmakers deem too risky.
California Gov. Gavin Newsom signed a bill last month that authorizes a statewide Medicaid contract for HMO giant Kaiser Permanente. But details still need to be worked out in a memorandum of understanding.
The president has directed the Federal Trade Commission to carefully consider health industry mergers that may stymie competition and drive up prices. The new Democratic majority appears eager to look beyond traditional hospital consolidations to deals that involve products, services, or staffing.
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail.
The FDA has approved a cannabis-derived drug, Epidiolex, to treat some forms of epilepsy. Now people who have other forms of the condition are using over-the-counter CBD products in hopes of taming their seizures. But doctors and patients worry about the unregulated world of CBD, in which product ingredients can be a mystery.
This episode is an interview with Dr. Thomas Fisher, author of "The Emergency: A Year of Healing and Heartbreak in a Chicago ER."
© 2026 KFF